Porcine FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag, produced by co-expression of FCGRT and B2M, has a calculated MW of 32.3 kDa (FCGRT) and 12.8 kDa (B2M). Subunit FCGRT is fused with a polyhistidine tag at the C-terminus and subunit Beta-2 microglobulin (B2M) is fused with a Strep II tag at the C-terminus. The reducing (R) protein migrates as 32-35 kDa (FCGRT) and 14 kDa (B2M) respectively.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Porcine FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Porcine FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (Cat. No. FCM-P5280) was more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.
Porcine FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (Cat. No. FCM-P5280) captured on CM5 Chip via anti-His antibody can bind Herceptin® with an affinity constant of 13.8 nM as determined in SPR assay (Biacore 8K) (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.